Literature DB >> 22580196

Vaccines against mucosal infections.

Jan Holmgren1, Ann-Mari Svennerholm.   

Abstract

There remains a great need to develop vaccines against many of the pathogens that infect mucosal tissues or have a mucosal port of entry. Parenteral vaccination may protect in some instances, but usually a mucosal vaccination route is necessary. Mucosal vaccines also have logistic advantages over injectable vaccines by being easier to administer, having less risk of transmitting infections and potentially being easier to manufacture. Still, however, only relatively few vaccines for human use are available: oral vaccines against cholera, typhoid, polio, and rotavirus, and a nasal vaccine against influenza. For polio, typhoid and influenza, in which the pathogens reach the blood stream, there is also an injectable vaccine alternative. A problem with available oral live vaccines is their reduced immunogenicity when used in developing countries; for instance, the efficacy of rotavirus vaccines correlates closely with the national per capita income. Research is needed to define the impact of factors such as malnutrition, aberrant intestinal microflora, concomitant infections, and preexisting immunity as well as of host genetic factors on the immunogenicity of these vaccines.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580196     DOI: 10.1016/j.coi.2012.03.014

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  51 in total

1.  Oral delivery of tumor microparticle vaccines activates NOD2 signaling pathway in ileac epithelium rendering potent antitumor T cell immunity.

Authors:  Wenqian Dong; Huafeng Zhang; Xiaonan Yin; Yuying Liu; Degao Chen; Xiaoyu Liang; Xun Jin; Jiadi Lv; Jingwei Ma; Ke Tang; Zhuowei Hu; Xiaofeng Qin; Bo Huang
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

2.  Antibodies Damage the Resilience of Fimbriae, Causing Them To Be Stiff and Tangled.

Authors:  Bhupender Singh; Narges Mortezaei; Stephen J Savarino; Bernt Eric Uhlin; Esther Bullitt; Magnus Andersson
Journal:  J Bacteriol       Date:  2016-12-13       Impact factor: 3.490

Review 3.  Contribution of Maternal Immunity to Decreased Rotavirus Vaccine Performance in Low- and Middle-Income Countries.

Authors:  Katayi Mwila; Roma Chilengi; Michelo Simuyandi; Sallie R Permar; Sylvia Becker-Dreps
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

4.  Vaccines against poverty.

Authors:  Calman A MacLennan; Allan Saul
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

Review 5.  Mucosal vaccines against respiratory syncytial virus.

Authors:  Kejian Yang; Steven M Varga
Journal:  Curr Opin Virol       Date:  2014-04-29       Impact factor: 7.090

6.  Antibiotic treatment suppresses rotavirus infection and enhances specific humoral immunity.

Authors:  Robin Uchiyama; Benoit Chassaing; Benyue Zhang; Andrew T Gewirtz
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

Review 7.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

8.  Prediction of Burkholderia pseudomallei DsbA substrates identifies potential virulence factors and vaccine targets.

Authors:  Ben Vezina; Guillaume A Petit; Jennifer L Martin; Maria A Halili
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

9.  Acute effects of rotavirus and malnutrition on intestinal barrier function in neonatal piglets.

Authors:  Sheila K Jacobi; Adam J Moeser; Anthony T Blikslager; J Marc Rhoads; Benjamin A Corl; Robert J Harrell; Jack Odle
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

10.  Alga-produced cholera toxin-Pfs25 fusion proteins as oral vaccines.

Authors:  James A Gregory; Aaron B Topol; David Z Doerner; Stephen Mayfield
Journal:  Appl Environ Microbiol       Date:  2013-04-19       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.